Ai strategy independent review

• 10 Oct, 2025
• • AI Strategy

The Second Opinion Every Board Needs on Its AI Strategy

When a management team presents an AI strategy to its board, there is a structural problem with the information flow that almost nobody in the room acknowledges. The people presenting the strategy are the same people who will be asked to execute it. They have career interests in its approval. They've spent weeks or months developing a position on where to invest and how to organize delivery. The strategy they're presenting is, inevitably, a strategy they believe in — and belief in one's own strategy is a particular kind of bias that is invisible to the person who holds it. The board's job is to scrutinize and approve, not to trust and endorse. But scrutinizing a technical and organizational strategy you didn't develop, in a domain you may not have deep experience in, using information provided by the people who want you to approve it, is genuinely hard. And the standard remedies — board education programs, independent non-executives with technology backgrounds, AI advisory reports — address the knowledge gap without addressing the conflict of interest. What addresses the conflict of interest is an independent review: an assessment of the AI strategy by someone with no financial interest in the approval or execution, commissioned by the board rather than by management. The structural conflict Most AI strategies presented to boards are management-produced documents. Sometimes they're supplemented by external advisors — consulting firms that were hired to help develop the strategy. Neither of these sources is independent. Management is presenting a strategy it developed and will implement. Its incentives are aligned with approval and the resources that follow. The consulting firm that helped develop the strategy has a commercial interest in the engagement and often a follow-on interest in the delivery work that the strategy will generate. Neither party is well-positioned to give the board an honest assessment of the strategy's weaknesses. This isn't a criticism of management or of consulting firms. It's a description of how commercial relationships work. The party with execution responsibility designs the strategy in a way that reflects their capabilities, their risk tolerance, and their organizational interests. These are legitimate inputs. They're also not the same as an independent assessment of whether the strategy is optimal for the organization. In financial audit, this problem is addressed by having the auditors appointed by and accountable to the board, not management. In strategy review, there's no equivalent standard. The independent AI review is an attempt to apply the same logic. What the review actually examines An independent AI strategy review is not a technical audit. It's an examination of whether the strategy the board is being asked to approve is coherent, realistic, and adequately governed. Coherence of the strategy. Does the AI investment portfolio connect to a defensible view of where the organization can create competitive advantage? Is there a logic to the use case selection that goes beyond "these are the best ideas we could generate internally"? Do the proposed investments reinforce each other, or are they independent bets without a strategic rationale? Realism of the execution plan. Are the timelines grounded in what comparable programs have actually taken? Are the resource requirements — budget, talent, data infrastructure — consistent with what the ambition requires? Are the risks to the timeline identified and given honest probability assessments, or are they listed as mitigations that assume away the uncertainty? Completeness of the risk picture. Does the strategy document the downside scenarios as clearly as the upside scenarios? Is the regulatory exposure understood? Are the data dependencies identified? Is the vendor concentration risk assessed? Does the governance structure address who is accountable when things go wrong? Adequacy of the governance framework. Is there a clear accountability structure for each AI investment? Is there a monitoring and reporting framework that will give the board real visibility into program health, not just progress updates? Is there a defined threshold at which the board would be asked to make a go/no-go decision on continued investment? A review that finds the strategy coherent, realistic, and adequately governed with specific evidence for each conclusion is a meaningful endorsement. A review that finds gaps — and most strategies have some — gives the board the information it needs to ask for revisions before approval, rather than discovering the gaps through program failure after the fact. What genuine independence requires Not all external reviews are independent in a meaningful sense. Independence has specific characteristics that are worth defining before commissioning a review. No financial interest in the outcome. A firm that is positioned to win delivery work based on the strategy's approval is not independent of the approval decision. This eliminates most large consulting firms, who treat strategy work as a pipeline for delivery revenue. Independence requires a reviewer with no follow-on commercial interest in what happens after the review. No prior relationship with the management team proposing the strategy. A firm that has a longstanding advisory relationship with management is not independent of management's perspective. The relationship will have shaped the reviewer's view of what management is capable of, what organizational dynamics are at play, and where to push and where to accommodate. Accountability to the board, not management. The reviewer should be commissioned by the board (typically through the chair or the audit/risk committee), report directly to the board, and have no obligation to accommodate management preferences in the findings. This requires explicit structuring at the outset — if management controls the engagement, the incentive structure will drift toward validation rather than assessment. Domain expertise sufficient to assess the claims. A reviewer who cannot assess whether an AI timeline is realistic, whether a talent plan is sufficient, or whether a technical architecture is appropriate for the use case can assess governance and financial logic but not technical strategy. For AI reviews, domain expertise is not optional. How to commission it without creating a political crisis The way an independent AI review is positioned internally determines whether it becomes a useful governance tool or a political problem. Framing it as a governance standard rather than a vote of no confidence in management makes a significant difference. The analogy to financial audit is useful here — boards don't commission financial audits because they distrust management; they commission them because independent verification is a governance standard. AI investments, as they become material to organizational strategy, warrant the same standard. Involving management in defining the scope while maintaining board ownership of the engagement maintains goodwill without compromising independence. Management can identify the key decisions they want the review to inform, the areas of most uncertainty, and the aspects of the strategy they're most confident in. This information is useful to the reviewer. It doesn't give management the ability to shape the conclusions. Sharing the findings with management before presenting to the full board — not to allow revision, but to allow factual corrections and context — reduces the likelihood that the review produces findings that management contests as factually inaccurate, which derails the board conversation. This is standard practice in financial audit. The fiduciary dimension Directors who approve material AI investments are making decisions they can be held accountable for. The AI strategies being approved by boards today represent significant capital commitments, carry regulatory exposure in multiple jurisdictions, and create organizational dependencies that will be difficult to unwind if the strategy proves wrong. In that context, approving an AI strategy based solely on management's assessment of it — without independent verification of its coherence, realism, and risk profile — is a governance decision. It's not necessarily wrong, but it's a choice, and it's one that directors should make explicitly rather than by default. The independent review doesn't make the decision for the board. It gives the board the information it needs to make the decision well. That's the job the board is supposed to be doing — and in AI, where the knowledge gap between management and board is widest, it's the job that most benefits from independent support. The board that says "we approved an AI strategy based on management's recommendation, with external advisory support from the firm that helped develop it" is in a different position than the board that says "we approved an AI strategy after an independent review that assessed its coherence, realism, and risk profile and identified the following gaps we required to be addressed before approval." The difference is not primarily legal. It's the difference between a governance process that is real and one that is notional. Boards that have been through significant governance failures know that distinction matters — before the failure, not only after it.

Read full article